Marca Mista depositada no INPI em 03/04/2020 por Novo Nordisk A/S, processo nº 501542011, nas classes 01, 05, 09, 10, 41, 42, 44. Registro em vigor até 03/04/2030.
| Número do processo | 501542011 |
|---|---|
| Situação | Registro de marca em vigor (Madri) |
| Apresentação | Mista |
| Natureza | Madri Produto/Serviço |
| Data do depósito | 03/04/2020 |
| Data da concessão | 27/07/2021 |
| Vigência até | 03/04/2030 |
| Titular | Novo Nordisk A/S |
| UF · País | — · DK |
Chemical preparations for use in industry; chemical additives; chemical additives for use in the manufacture of pharmaceuticals, cosmetics, hair lotions, disinfectants; chemical diagnostic reagents for industrial use; chemical preparations for use in the oil industry.;
Pharmaceutical preparations for the treatment of diabetes and obesity; pharmaceutical preparations for haemostasis management and for the treatment of sickle cell disease; pharmaceutical preparations for the treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease; pharmaceutical preparations for hormone therapy and stem cells for medical purposes; drug delivery devices containing the abovementioned products; chemical preparations for use in medical devices.;
Electronic publications, namely, leaflets, books, booklets, handouts, magazines as well as medical, instructional and teaching material in the field of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; downloadbale electronic publications featuring electronic reports containing results from clinical trials and studies in the field of prevention and treatment of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; software applications for use with mobile devices for monitoring and the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; computer hardware and software, for use with medical injection devices for collecting, transmitting, and displaying medical data; medical software for the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; software as a medical device.;
Medical and surgical apparatus and instruments, namely, hypodermic syringes and pens; medical apparatus and instruments for reconstitution and injection of pharmaceutical preparations; medical apparatus and instruments, namely, injection devices for administration of pharmaceutical preparations, medical infusion pumps, infusion pump controllers, adhesive infusion devices; digitally connected medical devices for monitoring the dispensation of pharmaceutical preparations for use in connection with the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; medical and surgical apparatus and instruments, namely, injection devices for the administration of pharmaceutical preparations and the wireless transmission of medical data in connection with the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; medical devices, namely, automatic needle insertion devices, protection caps for hypodermic syringes and medical pens; needles for injections; cartridges and carpules for administration pharmaceutical preparations.;
Educational services, namely, organizing and conducting educational programmes, coaching and training services for patients and healthcare professionals related to management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; arranging and conducting of conferences, congresses, seminars, symposiums and workshops related to the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment.;
Providing scientific information on diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; providing websites and mobile apps featuring technology that enables users to record, track, and generate reports regarding the condition, treatment and the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; computer services, namely providing access to data concerning medical analysis and management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment.;
Providing medical services via websites and mobile apps for the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; providing medical information and medical counselling the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment.;
Receba um e-mail a cada novo despacho publicado na RPI para o processo 501542011 — exigência, oposição, deferimento, prazo de pagamento — e quando alguém depositar uma marca parecida.
Monitorar esta marca Ver marcas parecidas4 despacho(s) publicado(s) na Revista da Propriedade Industrial.
26.1.1 Círculos26.1.4 Dois círculos, duas elipses, um dentro do outro27.5.1 Letras apresentando um grafismo especial29.1.4 Azul3.4.1 Bovinos